3Eucker J,Eikel D,Heider U,et al.Liposomal daunorubicin (DaunoXome) in multiple myeloma:a modified VAD regimen using shortterm infusion.Anticancer D rugs,2003,14:793-799.
2Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents [ J ]. N Engl J Med, 1984,310:1353-1356.
3Alexandrakis MG, Passam FH, Sfiridaki K,et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival [ J ]. Leuk Res,2004,28 ( 3 ) :259-266.
4Eucker J, Eikel D, Heider U, et al. Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion [ J ]. Anticancer Drugs,2003,14 ( 10 ): 793-799.
5Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma[ J ]. Curr Treat Options Oncol,2003,4 (3) :239-246.
7Ossenkoppele GJ. Treatment of multiple myeloma in elderly patients. New developments [ J ]. Drugs Aging, 1997,11 ( 2 ): 152-164.
8Tribalto M, Amadori S, Cudillo L, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myloma: an Italian Multicenter Study [ J ]. Haematologica,2000,85( 1 ) :52-58.
3Ba ZR,Walker E.Karam MA,et aL.Lenalidomide and peGYlated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiplemyeloma:safety and efficacy.Ann Oncol,2006,17:1766-1771.
4Rajkumar SV,Gartz MA,Lacy MQ,et al.Thalidomide as initial therapy for early-stage myeloma.Leukemia,2003,4:775-779.
5Thompson JL.Hansen LA.Thalidomide dosing in patients with relapsed or refractory multiple myeloma.Ann Phamacother,2003,37:571-576.
6Hideshima T,Chauhan G,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myelonla cells to conventionaltherapy.Blood,2000,96:2943-2950.
